Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Nov 13, 2026
TickeronGET DAILY SIGNALS
BODI Stock Falls -25% in 30 Days After Q3 Results and Cautious Guidance

BODI Stock Falls -25% in 30 Days After Q3 Results and Cautious Guidance

Key Takeaways

  • BODI shares declined roughly 25% over the trailing 30 days, sliding from a closing price near $4.57 to about $3.43.
  • The move followed third-quarter 2026 results, where revenue of $45.19 million fell 24.5% year over year and missed consensus estimates, even as GAAP EPS of $0.38 beat expectations.
  • Fourth-quarter revenue guidance of $38 million to $42 million came in below consensus of roughly $47 million, adding pressure on the shares.
  • The company disclosed an early October restructuring that reduced its cost base by more than $30 million.
  • Several analysts lowered their price targets after the report, while overall ratings remained a mix of Buy and Neutral.
  • Over the trailing quarter, the stock has fallen roughly 36%, extending a longer pattern of revenue contraction.
  • Explore additional pages for BODI Price Targets, Earnings, and Forecast data to track the company's outlook.

Company Overview: The Beachbody Company (BODI)

The Beachbody Company, Inc. (BODI), also known as BODi, operates a fitness and nutrition business across the United States, Canada, the United Kingdom, and France. Its model blends a digital subscription platform with nutrition supplements and connected-fitness products. The streaming service Beachbody on Demand Interactive features programs such as P90X, Insanity, 21 Day Fix, and LIIFT4, while its nutrition offerings include Shakeology and Beachbody Performance supplements.

Investors track BODI closely as the company shifts from its legacy multi-level marketing approach toward a nutrition-led, multi-channel strategy that includes direct-to-consumer, Amazon, and retail channels. The transition aims to expand its market reach, though it has coincided with ongoing revenue declines. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

BODI Stock Performance: Last 30 Days and Trailing Quarter

Over the last 30 days, BODI shares have fallen roughly 25%, moving from a closing level near $4.57 to about $3.43. Much of the drop came in one session after the third-quarter earnings release, when the stock fell from $4.51 to close near $3.34.

The quarterly picture looks even weaker. Over the trailing three months, the stock has declined approximately 36% and now trades near the bottom of its 52-week range of roughly $3.16 to $16.87. The broader trend reflects persistent revenue contraction, cautious forward guidance, and a market reassessment of the turnaround timeline.

What Drove the Recent 30-Day Decline

The primary catalyst was the third-quarter 2026 earnings report released on November 10, 2026. Revenue of $45.19 million marked a 24.5% year-over-year decline and missed consensus expectations of roughly $52.6 million. While GAAP EPS of $0.38 and adjusted EPS of $0.09 beat estimates, and adjusted EBITDA stayed positive for a twelfth straight quarter at about $6.4 million, the market focused on the weak top line and soft outlook.

Management guided fourth-quarter revenue to $38 million to $42 million, below the consensus of approximately $47 million. The company also noted an early October restructuring that reduced its cost base by more than $30 million. In response, several analysts lowered price targets: Roth Capital cut its target to $5 from $9 (Neutral), Craig-Hallum to $8 from $18 (Buy), and Canaccord to $12 from $16 (Buy). From what I see, the combination of the revenue miss, conservative guidance, and reduced targets triggered the sharp single-day move.

Quarterly Trends and Strategic Shift

The quarterly decline fits a longer narrative where legacy businesses continue to shrink faster than newer nutrition and retail initiatives can compensate. While BODI has posted several consecutive quarters of positive net income and adjusted EBITDA through cost discipline, revenue has contracted as subscriber attrition persists and new customer acquisition stays uneven.

The pivot toward a nutrition-led, multi-channel model has included new launches such as P90X ready-to-drink energy cans and the INSANITY-branded Liquid Shock energy drink, along with planned programs like INSANITY: UNHINGED and the BODi 365 platform for 2027. These efforts have yet to generate enough traction to reverse the top-line trend, keeping sentiment cautious.

What Investors Should Watch Next

Looking ahead, attention will center on fourth-quarter revenue performance within the guided $38 million to $42 million range, especially around Black Friday and Cyber Monday. Progress on new customer acquisition in nutrition and across Amazon and retail channels will indicate whether the multi-channel strategy is gaining ground. Other areas include the rollout of new INSANITY and P90X products, the shift of supplement manufacturing to a turnkey model, and any further cost actions. Macro conditions, competitive pressures, and analyst revisions will also influence sentiment, with revenue stabilization remaining the central question for the stock.

AI Tools I Use for Stock Analysis

In my research process, I often turn to Tickeron’s AI Daily Buy/Sell Signals to cross-check patterns and signals on names like this. The platform helps surface relevant trading ideas across thousands of tickers and has become a regular part of how I evaluate opportunities without hours of manual work. It provides an additional layer of perspective that complements traditional fundamental review.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: BODI

Contributor

Dem Sem's AvatarDem Sem|Expert

BODI's RSI Oscillator stays in oversold zone for 2 days

It is expected that a price bounce should occur soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +2.37% 3-day Advance, the price is estimated to grow further. Considering data from situations where BODI advanced for three days, in 197 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

BODI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BODI as a result. In 88 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for BODI turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 41 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BODI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for BODI entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 24 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.832) is normal, around the industry mean (0.974). P/E Ratio (2.388) is within average values for comparable stocks, (-39.046). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (17.274). Dividend Yield (0.000) settles around the average of (0.979) among similar stocks. P/S Ratio (0.167) is also within normal values, averaging (71.888).

The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. BODI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BODI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Alphabet (NASDAQ:GOOGL), Alphabet (NASDAQ:GOOG), Meta Platforms (NASDAQ:META), Spotify Technology SA (NYSE:SPOT), Nebius Group N.V. (NASDAQ:NBIS), Baidu (NASDAQ:BIDU), Tencent Music Entertainment Group (NYSE:TME), Pinterest (NYSE:PINS), Snap (NYSE:SNAP), Zillow Group (NASDAQ:Z).

Industry description

Companies in this industry typically license software on a subscription basis and it is centrally hosted. Such products usually go by the names web-based software, on-demand software and hosted software. Cloud computing has emerged as a major force in this space, making it possible to save files to a remote database (without requiring them to be saved on local storage device); as long as a device has access to the web, it can access the data and the software programs to run it. This has in many cases facilitated cost efficiency, speed and security of data for businesses and consumers. Alphabet Inc., Facebook, Inc. and Yahoo! Inc. are some well-known names in the internet software/services industry.

Market Cap

The average market capitalization across the Internet Software/Services Industry is 126.04B. The market cap for tickers in the group ranges from 107 to 3.48T. GOOGL holds the highest valuation in this group at 3.48T. The lowest valued company is STBXF at 107.

High and low price notable news

The average weekly price growth across all stocks in the Internet Software/Services Industry was 2%. For the same Industry, the average monthly price growth was -3%, and the average quarterly price growth was -13%. ONFO experienced the highest price growth at 114%, while GIBO experienced the biggest fall at -57%.

Volume

The average weekly volume growth across all stocks in the Internet Software/Services Industry was 71%. For the same stocks of the Industry, the average monthly volume growth was 52% and the average quarterly volume growth was 7%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 42
P/E Growth Rating: 63
Price Growth Rating: 63
SMR Rating: 77
Profit Risk Rating: 93
Seasonality Score: 14 (-100 ... +100)
Real Time Patterns 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry InternetSoftwareServices

Industry
N/A
Address
400 Continental Boulevard
Phone
+1 310 883-9000
Employees
270
Web
https://www.thebeachbodycompany.com
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
Dell Technologies (DELL) fell roughly 23.7% over the last 30 days, sliding from a closing price of $451.71 on October 16, 2026, to $344.53 on November 13, 2026. The decline accelerated after the U.S. midterm elections, when investor concerns about potential AI and data-center regulation triggered a sharp sell-off across AI hardware names.
SKHY fell -6.87% to $122.74 by 10:04 a.m. ET, down $9.05 from Friday's close of $131.79, extending a premarket decline into the regular session. The drop was driven by a sector-wide AI chip selloff ahead of Nvidia's quarterly results on Tuesday, where CEO Jensen Huang's resignation has raised doubts about the durability of data-center spending that underpins high-bandwidth memory demand.
ACHR fell -7.44% in Monday's regular session, sliding from Friday's $4.03 close to $3.73 shortly after 10 a.m. ET — a third consecutive daily decline that pushed shares back toward their November 5 low. No verified news or fundamental catalyst found for today's leg lower; the selling extends the de-rating that followed Q3 results — revenue of just $5.1 million, a net loss widening 111% to $274.6 million, and price-target cuts from Cantor Fitzgerald, Needham and Canaccord.